Ceribell (CBLL) risk factors, FY2025 10-K

Other

1. 01Business and Industry Risk Factors100% rewritten
2. 02We have a limited operating history and have experienced rapid growth, which may strain our resources and make it difficult to evaluate our business and future prospects. If we are unable to manage our expansion effectively, our business could be materially and adversely affectedNew
3. 03We have a history of net losses, and we expect to incur additional substantial losses in the foreseeable future20% rewritten
4. 04We cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will be able to sustain or increase profitability. Our prior losses, combined with potential future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital
5. 05We operate in a highly competitive industry, and competitive pressures could have a material adverse effect on our business, financial condition, results of operations, and prospects
6. 06Adapting our manufacturing and production capacities to evolving patterns of demand is expensive, time-consuming, and subject to significant uncertainties. We may not be able to adequately predict emerging customer trends and may be unable to adjust our production and inventory levels in a timely manner
7. 07Changes in trade policy, tariffs, and our reliance on international manufacturing and supply chain operations expose us to foreign operational and trade risks that may adversely affect our business, results of operations, and financial conditionNew
8. 08Increased tariffs and countermeasures could raise costs, limit material availability, disrupt global supply chains, increase market volatility, and create operational challenges, materially adversely affecting our sales, gross margins, and customer demandNew
9. 09If we cannot innovate at the pace of our competitors, we may not be able to develop or exploit new technologies in time to remain competitive
10. 10Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information, and personal dataNew
11. 11Any future sales in international markets will subject us to additional costs and risks that may have a material adverse effect on our business, financial condition, results of operations, and prospects
12. 12If we fail to attract and retain senior management and other key personnel, our business may be materially and adversely affected
13. 13If we fail to maintain our culture, our business may be negatively affected
14. 14If we are unable to successfully develop new products and effectively manage their introduction or improve our existing products, our business may be adversely affected67% rewritten
15. 15the inability to sell our current or any future products
16. 16The size and expected growth of our addressable market has not been established with precision, and may be smaller than we estimate
17. 17Alternative technologies or therapies addressing seizure, non-convulsive status epilepticus or other indications we intend to expand into could materially adversely affect our business, financial condition, results of operations, and prospects
18. 18We may in the future be deemed to manufacture or contract to manufacture products that contain conflict minerals
19. 19Macroeconomic conditions could materially adversely affect our business, financial condition, results of operations, and prospects
20. 20Shutdowns of the U.S. federal government could materially adversely affect our business, financial condition, results of operations, and prospectsNew

Risk Related to Regulatory Matters

1. 21If adequate reimbursement becomes unavailable for the diagnostic tests using our products, it could diminish our sales or affect our ability to sell the Ceribell System profitably26% rewritten
2. 22models in the United States for how private payers and other governmental payers develop their coverage and reimbursement policies for medical devices. Some third-party payers may require pre-approval of coverage for new or innovative devices before they will reimburse healthcare providers who use such devicesNew
3. 23Our employees, consultants and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
4. 24Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could have a material adverse effect on our business, financial condition, results of operations, and prospects
5. 25Our products and operations are subject to extensive government regulation and oversight in the United States, and our failure to comply with applicable requirements could harm our business
6. 26Failure to maintain marketing authorizations for our products, or to timely obtain necessary marketing authorizations for our future products, may have a material adverse effect on our business, financial condition, results of operations, and prospects
7. 27the potential for marketing authorization regulations of the FDA to change significantly in a manner rendering our clinical data or regulatory filings insufficient for marketing authorization39% rewritten
8. 28Our clinical testing process is complex, lengthy, can be expensive, and carries uncertain outcomes. Future trials and studies by us or others may fail to replicate positive results observed to date78% rewritten
9. 29preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials, or have viewed such data in different ways than regulatorsNew
10. 30our current or future products may have undesirable side effects or other unexpected characteristics74% rewritten
11. 31Interim, “top-line,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
12. 32We are subject to ongoing regulatory review and scrutiny. Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market
13. 33Any of these sanctions could result in negative publicity, higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition, results of operations, and prospects
14. 34Our products must be manufactured in accordance with applicable laws and regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations
15. 35Legislative or regulatory reforms in the United States may make it more difficult and costly for us to manufacture, market, or distribute our products, or to obtain marketing authorizations for any future products55% rewritten
16. 36We face risks related to obtaining necessary foreign regulatory clearance or approvals
17. 37Failure to comply with the Foreign Corrupt Practices Act (the “FCPA”), economic and trade sanctions regulations, and similar laws could subject us to penalties and other adverse consequences63% rewritten

Risks Related to Our Reliance on Third Parties

1. 38Various factors outside our direct control may negatively impact our manufacturing of the Ceribell System, which could have a material adverse effect on our business, financial condition, results of operations, and prospects52% rewritten
2. 39adjust our manufacturing operations to reduce fixed costs, which could lead to uncertainty and delays in manufacturing times and quality during any transition periodNew
3. 40The occurrence of any of these issues could significantly harm our ability to manufacture our products and maintain sufficient quality standards, which would have a material adverse effect on our business, financial condition, results of operations, and prospects
4. 41We source and rely upon components and sub-assemblies of the Ceribell System, as well as manufacturing services from approved manufacturers and suppliers, some of which are single-source suppliers54% rewritten
5. 42to ensure the materials and components meet our requirements, there is a risk that they may not supply components that meet our requirements or supply components in a timely mannerNew
6. 43We rely on third parties to conduct and support our preclinical studies and clinical trials. These third parties may not properly and successfully carry out their contractual duties or meet expected deadlines, which could harm our ability to obtain marketing authorization of or commercialize future products we develop
7. 44Actual or perceived failures to comply with applicable data privacy and security laws, regulations, standards and other requirements could adversely affect our business, financial condition, results of operations, and prospects26% rewritten
8. 45We may face risks associated with our use and development of AI and machine learning models
9. 46Our business and operations may suffer in the event of information technology system failures, cyber attacks, or deficiencies in our cybersecurity93% rewritten
10. 47parties in conjunction with our business. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential InformationNew

Risks Related to Our Intellectual Property

1. 48Our success will depend on our and our licensors’ ability to obtain, maintain, enforce, and protect our intellectual property rights87% rewritten
2. 49If we fail to identify our patentable inventions or adequately protect our patent rights, the commercial value of our products, services or technologies may be adversely affected and our competitive position may be harmed
3. 50Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 51We may not be able to protect our intellectual property rights throughout the world75% rewritten
5. 52enforcement is not as strong as that in the United States. These products, services, or technologies may compete with our products, services, or technologies, and our patents or other intellectual property rights may not be effective or sufficient to prevent such competitionNew
6. 53If we cannot successfully enforce our intellectual property rights, the commercial value of our products, services, or technologies may be adversely affected and our competitive position may be harmed44% rewritten
7. 54We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, and unsuccessful, and could interfere with our ability to develop, manufacture, commercialize, import, or otherwise use our products, services, or technologies
8. 55pay the attorney’s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing, misappropriating, or otherwise violating
9. 56We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property rights
10. 57We depend on certain intellectual property rights that are licensed to us. We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture, commercialize, import, or use our current and/or future products, services, or technologies
11. 58If we are unable to protect the disclosure and use of our confidential information and trade secrets, the value of our products, services, and technologies and our business and competitive position could be harmed24% rewritten
12. 59If our trademarks and trade names are not adequately protected, we may not be able to build brand name recognition in our markets of interest and our competitive position may be harmed
13. 60Our products contain third-party open source software components and failure to comply with the terms of the underlying open source software licenses could restrict our ability to sell our products, affect our ability to protect our proprietary information, and subject us to possible litigation
14. 61We are subject to certain manufacturing restrictions related to licensed intellectual property rights that were developed with the financial assistance of United States government grants

Risks Relating to Financial and Accounting Matters

1. 62Our ability to use our net operating loss carryforwards and other tax attributes may be limited due to certain provisions of the Internal Revenue Code or state tax law29% rewritten
2. 63Realization of these NOLs depends on future taxable income, and there is a risk that our existing NOLs could expire unused and be unavailable to offset future taxable income, which could adversely affect our results of operations
3. 64Our effective tax rate may vary significantly from period to period
4. 65Changes in tax laws or tax rulings could adversely affect our effective tax rates, results of operations and financial condition
5. 66Our venture loan and security agreement contains restrictions that limit our flexibility in operating our business
6. 67enter into certain transactions with our affiliates
7. 68Our cash deposits with financial institutions exceed insured limits

Risks Relating to Ownership of Our Common Stock

1. 69We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
2. 70the date on which we are deemed to be a “large accelerated filer” under the Exchange Act37% rewritten
3. 71We incur significant costs as a result of operating as a public company. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would seriously harm our businessNew
4. 72We do not intend to pay dividends in the foreseeable future. As a result, your ability to achieve a return on your investment will depend on appreciation in the market price of our common stock
5. 73If our operating and financial performance in any given period does not meet the guidance provided to the public or the expectations of investment analysts, the market price of our common stock may decline42% rewritten
6. 74Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock
7. 75We may require additional capital to support business growth, and this capital might not be available on terms favorable to us, or at all, and may dilute existing stockholders’ ownership of our common stock
8. 76Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval
9. 77Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
10. 78Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
11. 79We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our Board of Directors or brought to enforce a right to indemnification
12. 80We may not retroactively amend our amended and restated bylaws provisions to reduce our indemnification obligations to directors, officers, employees, and agents
13. 81The market price of our common stock may be volatile, which could cause the value of your investment to decline68% rewritten
14. 82If securities or industry analysts do not continue to publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline42% rewritten
15. 83If we engage in acquisitions or strategic partnerships, it may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
16. 84our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs
17. 85interruption in our operations or the operations of third parties who supply components or other materials for our products may have a material adverse effect on our business, financial condition, results of operations, and prospects
18. 86We are subject to risks from legal and arbitration proceedings that may prevent us from pursuing our business activities or require us to incur additional costs in defending against claims or paying damages
19. 87Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
20. 88Our insurance may not cover all potential losses or liabilities that may arise